Our feasibility study demonstrates a translation of the experimental findings to the clinic, thus supporting the concept that RBM3 mRNA expression is temperature regulated in a TTM treated post-cardiac arrest cohort and could possibly contribute to the clinical efficacy of therapeutic hypothermia. The gene discussed is RBM3; the disease is cardiac arrest.